“We continue to make important progress in advancing THB335, our orally available KIT inhibitor, towards clinical trials in the first half of 2024, which we believe has the potential to be a transformative treatment for chronic spontaneous urticaria and other mast cell-driven diseases,” said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. “With the continued momentum of THB335 and our strong cash position, we are well-positioned for meaningful value creation in the next phase of our company’s growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on THRD:
- Third Harmonic Bio Announces Third Quarter 2023 Financial Results
- Third Harmonic Bio Announces Leadership Changes
- Third Harmonic Bio announces CSO Ray’s transition to SA, CFO Ho to depart
- Fourteen new option listings and three option delistings on October 18th
- Third Harmonic Bio files $400M mixed securities shelf
